AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HUM
  4. [Form 4] Humana Inc. Insider Trading Activity

[Form 4] Humana Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name 鈥淒yadic Applied BioSolutions.鈥� The filing clarifies that the legal corporate name remains 鈥淒yadic International, Inc.,鈥� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished鈥攏ot filed鈥攖hereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato il modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, l'azienda inizier脿 a operare con il nome commerciale 鈥淒yadic Applied BioSolutions.鈥� Il documento specifica che la ragione sociale legale rimane 鈥淒yadic International, Inc.,鈥� il ticker DYAI non cambia e la societ脿 continuer脿 a essere quotata sul Nasdaq Stock Market. La comunicazione 猫 fornita ai sensi della voce 7.01 (Regolamento FD) ed 猫 fornita come informazione - non come deposito ufficiale - quindi non comporta responsabilit脿 ai sensi della Sezione 18 n茅 impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto comunica esclusivamente la futura denominazione DBA e allega il comunicato stampa correlato come Allegato 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) present贸 un Formulario 8-K el 2 de julio de 2025 para informar una actualizaci贸n de marca. En 30 d铆as, la empresa comenzar谩 a operar bajo el nombre comercial 鈥淒yadic Applied BioSolutions.鈥� El documento aclara que el nombre legal corporativo sigue siendo 鈥淒yadic International, Inc.,鈥� el s铆mbolo DYAI no cambia y la empresa continuar谩 cotizando en el Nasdaq Stock Market. La divulgaci贸n se realiza bajo el 铆tem 7.01 (Regulaci贸n FD) y se proporciona como informaci贸n, no como un archivo oficial, por lo que no conlleva responsabilidad bajo la Secci贸n 18 ni impacto directo en los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estrat茅gicas; el informe 煤nicamente comunica la pr贸xima designaci贸n DBA y adjunta el comunicado de prensa relacionado como Anexo 99.1.

Dyadic International, Inc. (雮橃姢雼�: DYAI)電� 2025雲� 7鞗� 2鞚� 敫岆灉霌� 鞐呺嵃鞚错姼毳� 瓿奠嫓頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 30鞚� 頉� 須岇偓電� 鈥淒yadic Applied BioSolutions.鈥�霛茧姅 靸來樃搿� 鞓侅梾鞚� 鞁滌瀾頃� 鞓堨爼鞛呺媹雼�. 鞝滌稖 氍胳劀鞐愲姅 氩曥爜 氩曥澑氇呾潃 鞐爠頌� 鈥淒yadic International, Inc.鈥濎澊氅�, DYAI 韹办护電� 氤�瓴诫悩歆� 鞎婈碃 須岇偓電� 雮橃姢雼� 欤检嫕鞁滌灔鞐� 瓿勳啀 靸侅灔霅� 瓴冹瀯鞚� 氇呿檿頌� 頃橁碃 鞛堨姷雼堧嫟. 鞚� 瓿奠嫓電� 頃 7.01(Regulation FD)鞐� 霐半澕 鞝滉车霅橂┌, 瓿奠嫕 鞝滌稖鞚� 鞎勲媽 鞝滉车(furnished) 順曧儨搿�, 靹轨厴 18 毂呾瀯鞚� 鞐嗞碃 鞛鞝滍憸鞐� 歆侅爲鞝侅澑 鞓來枼鞚� 鞐嗢姷雼堧嫟. 鞛 雿办澊韯�, 鞖挫榿 氤�瓴� 霕愲姅 鞝勲灥鞝� 瓯半灅電� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞚措矆 氤搓碃靹滊姅 雼り皜鞓る姅 DBA 氇呾弓 氤�瓴届潉 鞎岆Μ瓿� 甏�霠� 氤措弰鞛愲毳� 攵�靻嶌劀 99.1搿� 觳秬頃橂姅 雮挫毄毵� 雼搓碃 鞛堨姷雼堧嫟.

Dyadic International, Inc. (Nasdaq : DYAI) a d茅pos茅 un formulaire 8-K le 2 juillet 2025 pour annoncer une mise 脿 jour de sa marque. Dans 30 jours, la soci茅t茅 commencera 脿 op茅rer sous le nom commercial 芦 Dyadic Applied BioSolutions. 禄 Le d茅p么t pr茅cise que le nom l茅gal de la soci茅t茅 reste 芦 Dyadic International, Inc. 禄, que le symbole DYAI ne change pas et que la soci茅t茅 continuera 脿 锚tre cot茅e sur le Nasdaq Stock Market. La communication est effectu茅e en vertu de l'article 7.01 (R猫glement FD) et est fournie 鈥� non d茅pos茅e 鈥� ce qui exclut toute responsabilit茅 en vertu de la Section 18 et n鈥檃 aucun impact direct sur les 茅tats financiers. Aucune donn茅e financi猫re, r茅vision op茅rationnelle ou transaction strat茅gique n鈥檈st incluse ; le rapport se limite 脿 annoncer la future d茅signation DBA et fournit le communiqu茅 de presse associ茅 en Annexe 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Markenupdate bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Handelsnamen 鈥濪yadic Applied BioSolutions.鈥� t盲tig sein. Die Einreichung stellt klar, dass der rechtliche Firmenname weiterhin 鈥濪yadic International, Inc.鈥� lautet, das DYAI-Tickersymbol unver盲ndert bleibt und das Unternehmen weiterhin an der Nasdaq-B枚rse gehandelt wird. Die Offenlegung erfolgt gem盲脽 Punkt 7.01 (Regulation FD) und wird als Bereitstellung 鈥� nicht als Einreichung 鈥� vorgenommen, wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operative 脛nderungen oder strategische Transaktionen enthalten; der Bericht informiert ausschlie脽lich 眉ber die bevorstehende DBA-Bezeichnung und enth盲lt die zugeh枚rige Pressemitteilung als Anlage 99.1.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Name-only rebranding; no change to DYAI鈥檚 financial outlook or Nasdaq listing鈥攐verall neutral.

Investors face no immediate economic consequences from the new DBA. The filing contains no revenue, cost, or guidance updates, and the legal entity, reporting obligations, and ticker symbol remain intact. As such, valuation models and risk profiles should remain unchanged. Branding exercises can signal strategic repositioning, but without supporting detail this event is non-material for near-term cash flows or capital structure.

TL;DR: Administrative disclosure compliant with Reg FD; governance impact minimal.

The company properly used Item 7.01 to furnish market-wide notice, limiting liability exposure. Because the legal name is preserved, charter documents and existing contracts require no amendments. The 30-day lead time affords counterparties notice, while retaining the DYAI symbol avoids market-confusion. Overall governance risk remains unchanged.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato il modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, l'azienda inizier脿 a operare con il nome commerciale 鈥淒yadic Applied BioSolutions.鈥� Il documento specifica che la ragione sociale legale rimane 鈥淒yadic International, Inc.,鈥� il ticker DYAI non cambia e la societ脿 continuer脿 a essere quotata sul Nasdaq Stock Market. La comunicazione 猫 fornita ai sensi della voce 7.01 (Regolamento FD) ed 猫 fornita come informazione - non come deposito ufficiale - quindi non comporta responsabilit脿 ai sensi della Sezione 18 n茅 impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto comunica esclusivamente la futura denominazione DBA e allega il comunicato stampa correlato come Allegato 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) present贸 un Formulario 8-K el 2 de julio de 2025 para informar una actualizaci贸n de marca. En 30 d铆as, la empresa comenzar谩 a operar bajo el nombre comercial 鈥淒yadic Applied BioSolutions.鈥� El documento aclara que el nombre legal corporativo sigue siendo 鈥淒yadic International, Inc.,鈥� el s铆mbolo DYAI no cambia y la empresa continuar谩 cotizando en el Nasdaq Stock Market. La divulgaci贸n se realiza bajo el 铆tem 7.01 (Regulaci贸n FD) y se proporciona como informaci贸n, no como un archivo oficial, por lo que no conlleva responsabilidad bajo la Secci贸n 18 ni impacto directo en los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estrat茅gicas; el informe 煤nicamente comunica la pr贸xima designaci贸n DBA y adjunta el comunicado de prensa relacionado como Anexo 99.1.

Dyadic International, Inc. (雮橃姢雼�: DYAI)電� 2025雲� 7鞗� 2鞚� 敫岆灉霌� 鞐呺嵃鞚错姼毳� 瓿奠嫓頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 30鞚� 頉� 須岇偓電� 鈥淒yadic Applied BioSolutions.鈥�霛茧姅 靸來樃搿� 鞓侅梾鞚� 鞁滌瀾頃� 鞓堨爼鞛呺媹雼�. 鞝滌稖 氍胳劀鞐愲姅 氩曥爜 氩曥澑氇呾潃 鞐爠頌� 鈥淒yadic International, Inc.鈥濎澊氅�, DYAI 韹办护電� 氤�瓴诫悩歆� 鞎婈碃 須岇偓電� 雮橃姢雼� 欤检嫕鞁滌灔鞐� 瓿勳啀 靸侅灔霅� 瓴冹瀯鞚� 氇呿檿頌� 頃橁碃 鞛堨姷雼堧嫟. 鞚� 瓿奠嫓電� 頃 7.01(Regulation FD)鞐� 霐半澕 鞝滉车霅橂┌, 瓿奠嫕 鞝滌稖鞚� 鞎勲媽 鞝滉车(furnished) 順曧儨搿�, 靹轨厴 18 毂呾瀯鞚� 鞐嗞碃 鞛鞝滍憸鞐� 歆侅爲鞝侅澑 鞓來枼鞚� 鞐嗢姷雼堧嫟. 鞛 雿办澊韯�, 鞖挫榿 氤�瓴� 霕愲姅 鞝勲灥鞝� 瓯半灅電� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞚措矆 氤搓碃靹滊姅 雼り皜鞓る姅 DBA 氇呾弓 氤�瓴届潉 鞎岆Μ瓿� 甏�霠� 氤措弰鞛愲毳� 攵�靻嶌劀 99.1搿� 觳秬頃橂姅 雮挫毄毵� 雼搓碃 鞛堨姷雼堧嫟.

Dyadic International, Inc. (Nasdaq : DYAI) a d茅pos茅 un formulaire 8-K le 2 juillet 2025 pour annoncer une mise 脿 jour de sa marque. Dans 30 jours, la soci茅t茅 commencera 脿 op茅rer sous le nom commercial 芦 Dyadic Applied BioSolutions. 禄 Le d茅p么t pr茅cise que le nom l茅gal de la soci茅t茅 reste 芦 Dyadic International, Inc. 禄, que le symbole DYAI ne change pas et que la soci茅t茅 continuera 脿 锚tre cot茅e sur le Nasdaq Stock Market. La communication est effectu茅e en vertu de l'article 7.01 (R猫glement FD) et est fournie 鈥� non d茅pos茅e 鈥� ce qui exclut toute responsabilit茅 en vertu de la Section 18 et n鈥檃 aucun impact direct sur les 茅tats financiers. Aucune donn茅e financi猫re, r茅vision op茅rationnelle ou transaction strat茅gique n鈥檈st incluse ; le rapport se limite 脿 annoncer la future d茅signation DBA et fournit le communiqu茅 de presse associ茅 en Annexe 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Markenupdate bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Handelsnamen 鈥濪yadic Applied BioSolutions.鈥� t盲tig sein. Die Einreichung stellt klar, dass der rechtliche Firmenname weiterhin 鈥濪yadic International, Inc.鈥� lautet, das DYAI-Tickersymbol unver盲ndert bleibt und das Unternehmen weiterhin an der Nasdaq-B枚rse gehandelt wird. Die Offenlegung erfolgt gem盲脽 Punkt 7.01 (Regulation FD) und wird als Bereitstellung 鈥� nicht als Einreichung 鈥� vorgenommen, wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operative 脛nderungen oder strategische Transaktionen enthalten; der Bericht informiert ausschlie脽lich 眉ber die bevorstehende DBA-Bezeichnung und enth盲lt die zugeh枚rige Pressemitteilung als Anlage 99.1.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HILZINGER KURT J
(Last) (First) (Middle)
HUMANA INC.
500 W. MAIN STREET
(Street)
LOUISVILLE KY 40202
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HUMANA INC [ HUM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Humana Common 19,448 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(1) (1) (1) (1) Humana Common 24,034 24,034(1) D
Restricted Stock Units(2) (2) (2) (2) Humana Common 2,753 2,753 D
Restricted Stock Units(3) (3) 06/30/2025 A 399 (3) (3) Humana Common 399 $242.815 15,044 D
Explanation of Responses:
1. Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.
2. Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
3. Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.
Kurt J. Hilzinger 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Why is Dyadic International (DYAI) issuing an 8-K on July 2, 2025?

To announce that it will begin doing business as Dyadic Applied BioSolutions effective in 30 days.

When does the new DBA "Dyadic Applied BioSolutions" become effective?

The change takes effect 30 days after the July 2, 2025 press release.

Will Dyadic鈥檚 legal corporate name or Nasdaq ticker change?

No. The legal name remains Dyadic International, Inc. and the ticker stays DYAI.

Does the rebranding affect Dyadic鈥檚 financial statements or guidance?

The 8-K includes no financial data and states the information is furnished, not filed; financials are unaffected.

Where can investors read the full press release about the name change?

It is filed as Exhibit 99.1 to the Form 8-K dated July 2, 2025.

Which SEC item does Dyadic use to disclose the DBA change?

Item 7.01 (Regulation FD Disclosure).
Stock HUM logo
Humana

NYSE:HUM

HUM Rankings

#536 Ranked by Market Cap
#1588 Ranked by Dividends

HUM Latest News

Jul 22, 2025
Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process
Jul 15, 2025
Humana Simplifies Access to Coverage and Care Information
Jul 14, 2025
Inaugural Humana Cognitive Games to Celebrate Healthy Aging and Inspire Whole-Person Wellness
Jul 9, 2025
Humana Inc. to Release Second Quarter 2025 Results on July 30, 2025
Jul 8, 2025
Humana Foundation Responds to Central Texas Flood Tragedy with $500,000 in Recovery Support

HUM Latest SEC Filings

Jul 2, 2025
[Form 4] Humana Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Humana Inc. Insider Trading Activity

HUM Stock Data

28.62B
120.39M
0.2%
97.78%
3.03%
Healthcare Plans
Hospital & Medical Service Plans
United States
LOUISVILLE